Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 30;8(12):e82879.
doi: 10.1371/journal.pone.0082879. eCollection 2013.

Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders

Affiliations

Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders

Michael Zech et al. PLoS One. .

Abstract

Niemann-Pick type C (NPC) disease is a rare autosomal-recessively inherited lysosomal storage disorder caused by mutations in NPC1 (95%) or NPC2. Given the highly variable phenotype, diagnosis is challenging and particularly late-onset forms with predominantly neuropsychiatric presentations are likely underdiagnosed. Pathophysiologically, genetic alterations compromising the endosomal/lysosomal system are linked with age-related neurodegenerative disorders. We sought to examine a possible association of rare sequence variants in NPC1 and NPC2 with Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD) and progressive supranuclear palsy (PSP), and to genetically determine the proportion of potentially misdiagnosed NPC patients in these neurodegenerative conditions. By means of high-resolution melting, we screened the coding regions of NPC1 and NPC2 for rare genetic variation in a homogenous German sample of patients clinically diagnosed with PD (n = 563), FTLD (n = 133) and PSP (n = 94), and 846 population-based controls. The frequencies of rare sequence variants in NPC1/2 did not differ significantly between patients and controls. Disease-associated NPC1/2 mutations were found in six PD patients (1.1%) and seven control subjects (0.8%), but not in FTLD or PSP. All rare variation was detected in the heterozygous state and no compound heterozygotes were observed. Our data do not support the hypothesis that rare NPC1/2 variants confer susceptibility for PD, FTLD, or PSP in the German population. Misdiagnosed NPC patients were not present in our samples. However, further assessment of NPC disease genes in age-related neurodegeneration is warranted.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: MZ has received travel expenses form Actelion Pharmaceuticals Ltd. FC has received funding for travel from Medtronic. AJ has received funding for travel from Allergan and Ipsen Pharmaceuticals. BM received travel compensation from Novartis and Boehringer-Ingelheim, lecturing fees from Orion and Glaxo-Smith-Kline, grant support from GE Healthcare, Boehringer-Ingelheim, Desitin, TEVA-Pharma, and serves as a consultant to Bayer-Schering Pharma and the Michael J. Fox Foundation for Parkinson's Disease Research. MV has received travel expenses, carried out paid and unpaid consultancy work, and presentation honoraria from Actelion Pharmaceuticals Ltd., and has received travel expenses, presentation honoraria, and been invited to meetings funded and organized by Genzyme Corporation and Shire HGT. PLa has received presentation honoraria from Actelion Pharmaceuticals France. HK has received travel expenses, carried out paid consultancy work, and received presentation honoraria from Actelion Pharmaceuticals Ltd. CT serves on scientific advisory boards for Boehringer Ingelheim and UCB, has received speaker honoraria from Boehringer Ingelheim, UCB, and Mundipharma as well as travel compensation from UCB, Boehringer-Ingelheim, and Mundipharma. TMei was supported by the German Network for Mitochondrial Disorders (mitoNET 01GM0867), the European Commission Seventh Framework Program (N. 261123), Genetic European Variation in Disease Consortium, and German Ministry for Education and Research (01GR0804-4). BH serves on a scientific advisory board for Merz Pharmaceuticals; has received funding for travel from Biogen Idec, Ipsen, and Merz Pharmaceuticals; has received speaker honoraria from Allergan and Ipsen, and receives research support from Ipsen and the DFG. SL received grants from UCB Pharma, TEVA, Boehringer, Grünenthal, Orion. JW serves on a scientific advisory board for UCB; has received speaker honoraria from UCB and Boehringer Ingelheim; has filed a patent re: Winkelmann et al. Nat Genet 2007; and receives research support from the German RLS foundation, the Deutsche Forschungsgemeinschaft (DFG) and the Fritz Thyssen Foundation. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

References

    1. Group N-CGW (2009) Wraith JE, Baumgartner MR, Bembi B, Covanis A, et al. (2009) Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 98: 152–165. - PubMed
    1. Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5: 16. - PMC - PubMed
    1. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, et al. (2012) Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 106: 330–344. - PubMed
    1. Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, et al. (1988) Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet 33: 331–348. - PubMed
    1. Sevin M, Lesca G, Baumann N, Millat G, Lyon-Caen O, et al. (2007) The adult form of Niemann-Pick disease type C. Brain 130: 120–133. - PubMed

Publication types